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Objectives: The aim of this study was to assess the role of adding gabapentin (Neurontin) to the
prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI).
Methods: An observational pilot study was performed on 20 consecutive patients with CLI who were
taking all experiencing rest pain despite high dose opiate analgesia. None of the patients were candidates
for reconstructive surgery or angioplasty due to the anatomical distribution of their vascular disease or
presence of co-morbidities. Gabapentin was commenced at 300 mg daily and titrated to 300 mg tds over
3 days. Doses were then increased up to 600 mg tds as indicated. Pain was assessed by visual analogue
scoring at baseline, 4, 7, 14 and 28 days. Improvements in night pain and need for opiates were also
noted. The primary end point was pain score at 28 days or until surgical intervention/death if these
points occurred sooner.
Results: Nineteen of 20 reported signiﬁcant night pain, 15 had gangrene or ulceration. Seventeen of 20
patients completed the full observation period of 28 days. Two patients required an operation and 1
patient died of a myocardial infarct. The pain scores fell from a median of 9 (inter-quartile range [IQR])
(7–9) at baseline to 5 (3–6) at 28 days. Improvement in pain scores was observed in 15/17 patients. Of the
17 completing the study, 16 had experienced rest pain at the time of referral of which 15 had signiﬁcant
beneﬁt with gabapentin.
Conclusions: The study has demonstrated that gabapentin is a useful adjuvant in the management of CLI
and leads to signiﬁcant reductions in pain scores and improves night pain for most patients.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
CLI is deﬁned as chronic ischaemic rest pain, ulcers or gangrene
attributable to objectively proven arterial occlusive disease.1 The term
CLI implies chronicity and is to be distinguished from acute limb
ischaemia and should be conﬁrmed by determination of an ankle
systolic pressure50 mmHg, a toe pressure of<30–50 mmHg or an
ankle brachial pressure index (ABPI) of <0.5. It has been estimated
that 20% of patients with intermittent claudicationwill deteriorate to
a state of CLI giving a calculated prevalence for CLI of 1% in men aged
over 55 years.2
Critical limb ischaemia (CLI) poses a number of difﬁcult chal-
lenges to vascular surgeons as it is a limb-threatening condition
associated with disabling and difﬁcult to manage pain, and for
those suitable for surgery – either reconstructive or amputation,ycoed, Pontypridd, Rhondda
. Morris-Stiff).
iates Ltd. Published by Elsevier Ltthere is a high prevalence of concomitant cardiovascular disease
leading to signiﬁcant morbidity and mortality.3
Managementof CLI is directed at pain control andmaintenanceof
limb integrity. A studyby the JointVascular ResearchGroup (JVRG)of
409 patients presenting with CLI noted that 60% were treated
primarily by vascular reconstruction or angioplasty; 20% required
primary amputation and 20% some other form of temporising
treatment.4 When the cohort was reviewed at 1 year: 25% had
undergoneamputation;55%hadboth limbs intact; and20%haddied.
For those not suitable for angioplasty or reconstructive surgery,
and for patients whose symptoms recur following primary treat-
ment, the mainstay of treatment is either amputation or conser-
vative management through provision of adequate analgesia.
Amputation itself, despite being a relatively quick and simple
procedure, is associated with a signiﬁcant peri-operative mortality
of 5–20% with a 2-year mortality of 25–30% and a 5-year mortality
of 50–75%.5 There is also considerable morbidity in particular
phantom limb pain.
The prescription of analgesia in CLI had traditionally revolved
around the use of opioid agents. Whilst the pathogenesis of CLId. All rights reserved.
Tab1e 1
Clinical features and cardiovascular risk factor proﬁles of patients prescribed
gabapentin.
Frequency n (%)
Clinical features
Rest pain 17 (85%)
Night pain 19 (95%)
Ulceration 12 (60%)
Gangrene 7 (35%)
Cardiovascular risk factors
Hypertension 18 (90%)
Hypercholesterolaemia 14 (70%)
Angina 11 (55%)
Myocardial infarct 8 (40%)
Transient ischaemic attack 5 (25%)
Cerebrovascular accident 2 (10%)
Smoking (current or ex-smoker) 18 (90%)
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micro-circulations of the limb, the condition is not fully under-
stood. It has been suggested that neuropathic pain may be an
important element of CLI6,7 and this is certainly the case that
ischaemia is a recognised cause of neuropathic pain.8 If this is the
case, then other non-opioid agents may be of some clinical beneﬁt
and indeed avoid some of the troubling side-effects associated with
opioids. One such drug is gabapentin (Neurontin) which is
licensed for the treatment of all neuropathic pain conditions and
has certainly been demonstrated to be of beneﬁt in terms of pain
relief and quality of life in diabetic neuropathic pain.9
No studies have so far evaluated the role of gabapentin in
patients with peripheral vascular disease and there is only a single
case report documenting its use.10 The aim of this study was to
prospectively evaluate the clinical effects in terms of visual
analogue pain scores in a pilot study of patients with CLI who were
on high dose opioid analgesics and not candidates for reconstruc-
tive surgery or angioplasty.
2. Methods
Between April 2004 and April 2005, 20 consecutive patients
with critical limb ischaemia were recruited to this observational
pilot study. All patients were under the care of a single vascular
surgeon and all had CLI due to infragenicular peripheral vascular
disease that was not amenable to angioplasty or reconstructive
surgery (due to anatomical site or patient co-morbidities). In each
case CLI was conﬁrmed by the presence of an ankle systolic pres-
sure less than 50 mmHg.
All patients were taking high dose opioid analgesic agents, of
various types, at the time of recruitment which had failed to
adequately relieve the pain. The majority of patients were taking
a combination of sustained release and on demand preparations
either morphine sulphate or oxycodone. None of the patients had
previously been prescribed gabapentin.
Cardiovascular risk factors were noted including the presence of
a history of: hypertension; hypercholesterolaemia; angina;
myocardial infarction; transient ischaemic attack or cerebrovas-
cular accident. Smoking habit was also noted. Patients with
a history of diabetes were excluded.
Gabapentin was commenced at 300 mg daily and titrated to
300 mg tds over 3 days. Doses were then increased up to 600 mg
tds as indicated. Pain was assessed by visual analogue scoring at
baseline, 4, 7,14 and 28 days. Patients were asked tomark their pain
from 0 to 10 with 0 representing a pain free state and 10 being
equivalent to the worst pain ever on a linear analogue score.11
Treatment was carried out on an outpatient basis.
Improvements in night pain were noted as was any reduction in
the prescribed dose of opioid analgesics. The primary end point was
pain score at 28 days or until surgical intervention/death if these
points occurred sooner.
The median pain scores at the varying time periods were
compared to baseline levels using the Mann–Whitney U test with
statistical signiﬁcance assumed at the 5% level.
3. Results
The study population consisted of 11 males and 9 females with
a mean age of 68 years (Standard error of mean [SEM] 2.4 years).
The presenting features and cardiovascular risk factor proﬁles
are summarised in Table 1. Seventeen of 20 patients reported rest
pain, 19 had evidence of ulceration or gangrene and all bar 1
experienced night pain leading to disturbed sleep patterns.
None of these patients had undergone any previous lower limb
arterial surgery and presented with infragenicular disease.Seventeen patients completed the 28 day follow-up period and
did not undergo any amputation during this time. One patient was
admitted as an emergency due to the presence of gangrene then
developed chest pain at 14 days following commencement of
gabapentin. A myocardial infarct was conﬁrmed but despite
optimal medical management he died of his coronary event. Two
other patients showed no improvement in pain control necessi-
tating amputation at 17 and 21 days.
Of the 17 patients completing the study, the median dose of
gabapentin was 1271 mg. Four patients were adequately controlled
with 300 mg tds, 9 were on 1200 mg and the remainder were
prescribed 600 mg tds. Of those taking 1200 mg of gabapentin, the
additional drug dose was administered in the evening for night
pain. None of the patients reported any speciﬁc undesirable side-
effects related to gabapentin. In particular, daytime drowsiness did
not appear to be a problem.
The median pain score for this cohort, as assessed by a visual
analogue score, was 9 at presentation andwas signiﬁcantly reduced
compared with the baseline at each of the assessment points and
was 7 at 4 days; 7 at 7 days, 6 at 14 days and 5 at 28 days (Fig. 1.).
Only 2 patients completing the follow-up period failed to show an
improvement in pain scores. Of the 17 patients completing follow-
up, sixteen had reported night pain at the time of recruitment of
which 15 noted a signiﬁcant reduction in night pain allowing better
sleeping and a perceived improvement in the quality of life. In 5
patients, the improvement in pain control was signiﬁcant enough
to allow a reduction in the dose of opioid analgesics prescribed.
None of the patients required increased doses of opiates.4. Discussion
The primary ﬁnding of the study was that the addition of
gabapentin to the standard opioid prescriptions of patients with CLI
lead to a statistically signiﬁcant reduction in median pain scores
which was evident as soon as 4 days after commencing the new
therapy. At recruitment the median pain score was 9 and this
reduced sequentially over the course of the study to 5 at 28 days,
a decrease of 44%. These results would suggest that the pain of CLI
may include a component of neuropathic pain, possibly as a result
of ischaemia to the sensory nerves.6,7 In 5 cases the pain relief was
successful enough to allow partial withdrawal of opioid medica-
tions thus reducing the prevalence of side-effects of these drugs
which are extensive.
None of the patients reported any signiﬁcant complications
related to the gabapentin and none of the 3 who failed to complete
the follow-up withdrew due to drug-related side-effects. Two of
the 20 (10%) patients recruited ended up with an amputation and
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Fig. 1. Median pain scores at baseline and at intervals of 4, 7, 14, and 28 days following commencement on gabapentin.
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ﬁndings are in keeping with those of the JVRG which indicated
a signiﬁcant proportion of patients with CLI will require amputa-
tion and a large number will die as a result of cardiovascular
disease.4 In contrast to Woolf’s study, which reported the results of
all-comers with CLI, this study concentrated on theworst prognosis
group namely those patients not suitable for reconstruction due to
unfavourable anatomy or cardiovascular co-morbidities. It also
excluded diabetics, a group that is known to suffer from neuro-
pathic pain and to beneﬁt from gabapentin therapy.9 Therefore, it is
likely that if gabapentin were used in diabetic claudicants with CLI
the results may be even more striking.
This is the ﬁrst paper to investigate the role of gabapentin in
a series of patients with CLI. The only existing literature is a case
report published in 2005 of a 56 year old man with critical
ischaemia who beneﬁted signiﬁcantly from gabapentin.10
In addition, of those reporting night pain, 15 of the 16 patients
completing follow-up, reported a signiﬁcant improvement in the
severity of this symptom allowing them to obtain improved sleep.
Whilst a formal quality of life assessment was not part of the design
of this investigation, the majority of patients noted that improve-
ment in the quality of their sleep was a great beneﬁt to them.
The issue of night pain has for a long time been recognised as
being of great importance in CLI as for many patients, this is one of
the most crippling symptoms as it reduces their energy reserve for
the following day.12 Night pain occurs as a result of circadian
changes in blood pressure control leading to nocturnal hypotension
in an already ischaemic limb. It has been shown that the degree of
hypotension correlates with the severity of night pain.13 It may be
that the improved control of night painwas related in part to one ofthe documented side-effects of gabapentin namely somnolence.
However, as the majority of patients more than the baseline level of
gabapentin took additional doses at night, this did not affect their
level of daytime activity and drowsiness did not appear to be
a signiﬁcant problem.
The dose of gabapentin in this study was titrated to patient pain
levels rather than a ﬁxed drug level, and whilst signiﬁcant
improvement in pain scores and night painwere noted, it may have
been the case that increasing doses to 600 mg tds for all patients
would have lead to further improvements in symptomatic
outcome. However, it is impossible to be certain that this would not
have been associated with an increase in frequency of side-effects.
Further studies are planned to assess the role of intervention
with gabapentin earlier in peripheral vascular disease by assessing
its efﬁcacy in patients with signiﬁcant intermittent claudication
prior to the development of CLI to determine whether pharmaco-
therapy in addition to risk factor modiﬁcation and exercise
programs can reduce the proportion of patients developing CLI.
There is evidence that there is progressive neuro-degeneration
which commences in intermittent claudication and progresses as
the severity of the vascular disease progresses.14 Formal quality of
life studies will be included in these studies to conﬁrm the ﬁndings
of this observational study.
5. Conclusions
The study has demonstrated that the use of gabapentin as an
analgesic in the management of CLI and leads to signiﬁcant
reductions in pain scores and also improves night pain for the
majority of patients.
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